Bioventus Inc. Stock 12‑Month Price Target Cut to $17.4, Implies 32% Upside

What happened

The average 12-month price target for Bioventus Inc. from 5 analysts fell to $17.4 from $17.6, with forecasts ranging from $15 to $18 per share. The consensus rating stayed "Buy" with 5 Buys, 0 Holds and 0 Sells.

Confirmed

Global impact / market context

A lower average target means analysts collectively expect slightly less upside than before, even though all 5 still rate the stock a Buy. The unchanged rating suggests the small cut reflects fine-tuning of expectations rather than a shift in how analysts view the company.

Analyst inference

The target is based on the Nov. 2 closing price and implies about 32% potential upside, which means the stock price sits well below what analysts think it is worth. The $15 to $18 range shows analysts disagree on how much the shares could gain.

Analyst inference

What to watch

1. Watch whether the average target of $17.4 moves at the next update, since it already slipped from $17.6 and sits inside a $15 to $18 range. Confirmed
2. Watch for any change in the mix of Buy, Hold and Sell ratings, because all 5 analysts currently rate Bioventus a Buy and one downgrade would alter that picture. Proposed
3. Watch whether the 32% upside implied by the Nov. 2 closing price holds, because that gap depends on both the share price and the analyst targets moving over time. Analyst inference

Evidence

• Original source link unavailable